Antibody-Drug Conjugates: Technologies and Global Markets

The global sales of ADCs on the market are showing a rapid growth trend, with growth rates of 36.5% and 40.7% in 2022 and 2023, respectively, with the market reaching a value of $10.8 billion in 2023. The market is projected to grow to more than $47 billion by the end of 2029, with a robust projected CAGR of 28.4% during the forecast period. To date, fourteen ADCs have gained entry into the global market, of which only thirteen remain.

In recent years, the field of ADCs has advanced considerably. Their numerous limitations have been addressed and their potential has been proven as a versatile precision medicine class that could serve as an alternative to conventional chemotherapy. Technological advances, the growing number of cancer patients and the increasing demand for biologics to treat cancer are the prime factors driving the market for ADCs. Increasing funding and investments in the ADC market reflect robust market sentiments about the potential for ADC drugs to address unmet medical needs. Big pharmaceutical companies’ infrastructure, combined with ADC specialist companies’ know-how, could help further entrench ADCs in the treatment of multiple cancer types and expedite the development of the ADC field. The burgeoning clinical pipeline is an important driver of the ADC market.

The microtubule inhibitors market for antibody-drug conjugates is estimated to increase from $6.7 billion in 2023 to reach $25.7 billion by 2029, at a CAGR of 25.6% from 2024 through 2029. The DNA targeting agents market for antibody-drug conjugates is estimated to increase from $4.1 billion in 2023 to reach $21.1 billion by 2029, at a CAGR of 32.2% from 2024 through 2029.

Report Scope

This report focuses on the global market for antibody-drug conjugates (ADCs), offering an updated review that covers their fundamental design and use across different oncology fields. In this report, market segmentation is based on payload, linker, antibody, indications, and region. The report also discusses current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations, opportunities, and the latest trends in the ADC market are also discussed in the report.

The report only covers antibody-drug conjugates in which an antibody is conjugated with small-molecule cytotoxic agents (also called payload) through a linker. Alternative antibody conjugates, such as those involving antibodies linked to radioisotopes, are not covered in this report.

The report includes:

25 data tables and 45 additional tables
An updated review of the global market for antibody drug conjugates
Analyses of the global market trends, with data from 2021-2023, estimates for 2024, forecasts for 2025, and projections of compound annual growth rates (CAGRs) through 2029
Evaluation of the overall market for antibody drug conjugates, and corresponding market share analysis by payload type, linker type, antibody type, indication and region
Coverage of the latest approvals, recalls, safety alerts, and clinical trials; the technical issues related to human anti-mouse antibody (HAMA); and the factors affecting mAB drugs
Information about major and emerging technologies for the formulation of antibody drug conjugates and assessment of their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
Discussions of the market dynamics, opportunities and challenges
Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
Competitive intelligence, including companies’ market shares, recent M&A activity and venture funding
Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Daiichi Sankyo, Pfizer Inc., and Gilead Sciences

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Components of ADCs
Drug-to-antibody Ratio (DAR)
How ADCs Work
Advantages of ADCs
Conjugation Methods
Conventional Conjugation Method
Site-Specific Conjugation
Key ADC Targets
Approved ADCs

Chapter 3 Market Dynamics

Market Dynamics Snapshot
- Market Drivers
  - Rising Prevalence of Cancer and Unmet Need in Oncology
  - De-risked Development
  - Complexity of ADCs
  - Investor Confidence in ADC Therapeutic Modality
  - Support from Regulatory Agencies
- Limitations
  - Technical and Manufacturing Challenges
  - ADC Resistance

Chapter 4 Emerging Technologies and Developments

Bispecific or Dual-Targeted ADCs
Dual Payload ADCs
ADCs in Combination with Immune Checkpoint Inhibitors
B7-H3 Antibody Target
Site-specific Conjugation
Pipeline Analysis
Payload Type
Linker Type
Antibody Type
Indication Type
Target Type
Conjugation Method Type
Novel ADCs in Development, by Phase

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown
Market Analysis, by Payload Type
- Market Overview
- Market Revenue and Forecast
Market Analysis, by Linker Type
- Market Overview
- Market Revenue and Forecast
Market Analysis, by Type of Antibody
- Market Overview
- Market Revenue and Forecast
Market Analysis, by Indication
- Market Overview
- Market Revenue and Forecast
Market Analysis, by Region
- North America
- Europe
- Other Regions

Chapter 6 Competitive Intelligence

ADC Sales
Market Share Analysis

Chapter 7 Appendix

Methodology
Sources
Abbreviations

Company Profiles

AbbVie Inc.
ADC Therapeutics SA
Daiichi Sankyo Co. Ltd.
F. Hoffmann-La Roche Ltd.
Gilead Sciences Inc.
Pfizer Inc.

List of Tables

Summary Table: Global Market for ADCs, by Type of Payload, Through 2029
Table 1: Key Antigen Targets for ADCs
Table 2: Commercially Available ADCs: Key Components and Target Antigens
Table 3: Discontinued ADCs: Key Components and Target Antigens
Table 4: Acquisitions in the ADC Market, 2023 and 2024
Table 5: Recent Strategic Partnerships/Deals in the ADC Market
Table 6: ADCs Approved Under FDA’s Accelerated Approval Program
Table 7: Bispecific ADCs in Clinical Development
Table 8: ADCs in Combination with Immune Checkpoint Inhibitors
Table 9: ADC Candidates Targeted Against B7-H3
Table 10: Novel ADCs in Phase 2 or Phase 3 Trials, by Phase and Payload Type
Table 11: Novel ADCs in Phase 2 or Phase 3 Trials, by Phase and Linker Type
Table 12: Novel ADCs in Phase 2 or Phase 3 Trials, by Phase and Antibody Type
Table 13: Novel ADCs in Phase 2 or Phase 3 Trials for Selected Tumor Types
Table 14: Novel ADCs in Phase 2 or Phase 3 Trials, by Target Types
Table 15: ADCs in Phase 3 Clinical Trials
Table 16: ADCs in Phase 2 and Phase 3 Clinical Trials
Table 17: ADCs in Phase 2 Clinical Trials
Table 18: Commonly Used ADC Payloads
Table 19: Global Market for ADCs, by Type of Payload, Through 2029
Table 20: Cleavable Linkers in FDA-approved ADCs
Table 21: Non-cleavable Linkers in FDA-Approved ADCs
Table 22: Global Market for ADCs, by Type of Linker, Through 2029
Table 23: Global Market for ADCs, by Type of Antibody, Through 2029
Table 24: ADCs Approved for Breast Cancer Treatment
Table 25: ADCs Approved for Blood Cancer Treatment
Table 26: ADCs Approved for Bladder Cancer Treatment
Table 27: ADCs Approved for Cancers Other than Breast, Blood and Bladder Cancer
Table 28: Global Market for ADCs, by Indication, Through 2029
Table 29: Global Market for ADCs, by Region, Through 2029
Table 30: North American Market for ADCs, by Type of Payload, Through 2029
Table 31: North American Market for ADCs, by Type of Linker, Through 2029
Table 32: North American Market for ADCs, by Type of Antibody, Through 2029
Table 33: North American Market for ADCs, by Indication, Through 2029
Table 34: European Market for ADCs, by Type of Payload, Through 2029
Table 35: European Market for ADCs, by Type of Linker, Through 2029
Table 36: European Market for ADCs, by Type of Antibody, Through 2029
Table 37: European Market for ADCs, by Application, Through 2029
Table 38: Other Regions Market for ADCs, by Type of Payload, Through 2029
Table 39: Other Regions Market for ADCs, by Type of Linker, Through 2029
Table 40: Other Regions Market for ADCs, by Type of Antibody, Through 2029
Table 41: Other Regions Market for ADCs, by Application, Through 2029
Table 42: Sales of ADCs, 2021-2023
Table 43: Global Market Shares of Manufacturers/Marketers of ADCs, 2023
Table 44: Report Sources
Table 45: Abbreviations Used in This Report
Table 46: AbbVie Inc.: Company Snapshot
Table 47: AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 48: AbbVie Inc.: Product Portfolio
Table 49: AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 50: ADC Therapeutics SA: Company Snapshot
Table 51: ADC Therapeutics SA: Financial Performance, FY 2022 and 2023
Table 52: ADC Therapeutics SA: Product Portfolio
Table 53: ADC Therapeutics SA: News/Key Developments, 2022
Table 54: Daiichi Sankyo Co. Ltd.: Company Snapshot
Table 55: Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 56: Daiichi Sankyo Co. Ltd.: Product Portfolio
Table 57: Daiichi Sankyo Co. Ltd.: News/Key Developments, 2022-2024
Table 58: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 59: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 60: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 61: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 62: Gilead Sciences Inc.: Company Snapshot
Table 63: Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 64: Gilead Sciences Inc.: Product Portfolio
Table 65: Gilead Sciences Inc.: News/Key Developments, 2023 and 2024
Table 66: Pfizer Inc.: Company Snapshot
Table 67: Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 68: Pfizer Inc: Product Portfolio
Table 69: Pfizer Inc.: News/Key Developments, 2022-2024

List of Figures

Summary Figure: Global Market Shares of ADCs, by Type of Payload, 2023
Figure 1: Market Dynamics of Antibody-Drug Conjugates
Figure 2: Estimated New Cancer Cases Globally, 2022, 2045 and 2050
Figure 3: Key Considerations for Next-Generation ADCs
Figure 4: Novel ADCs in Clinical Development, by Clinical Trial Phase
Figure 5: Novel ADCs in Phase 2 or Phase 3 Trials, by Phase and Payload Type
Figure 6: Distribution Share of ADC Pipeline, by Conjugation Method
Figure 7: Global Market Shares of ADCs, by Type of Payload, 2023
Figure 8: Global Market Shares of ADCs, by Type of Linker, 2023
Figure 9: Global Market Shares of ADCs, by Type of Antibody, 2023
Figure 10: Global Blood Cancer Incidence, by Type, 2022 vs. 2045
Figure 11: Global Market Shares of ADCs, by Indication Type, 2023
Figure 12: Global Market Shares of ADCs, by Region, 2023
Figure 13: AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 14: AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 15: ADC Therapeutics SA: Revenue Share, by Business Unit, FY 2023
Figure 16: ADC Therapeutics SA: Revenue Share, by Region, FY 2023
Figure 17: Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 18: Daiichi Sankyo Co. Ltd.: Revenue Share, by Region, FY 2023
Figure 19: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 20: F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 21: Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 22: Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 23: Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 24: Pfizer Inc.: Revenue Share, by Region, FY 2023

Samples

LOADING...

Companies Mentioned

AbbVie Inc.
ADC Therapeutics SA
Daiichi Sankyo Co. Ltd.
F. Hoffmann-La Roche Ltd.
Gilead Sciences Inc.
Pfizer Inc.

Table Information

Report Attribute	Details
No. of Pages	89
Published	September 2024
Forecast Period	2024 - 2029
Estimated Market Value ( USD ) in 2024	$ 10.8 Billion
Forecasted Market Value ( USD ) by 2029	$ 47 Billion
Compound Annual Growth Rate	28.4%
Regions Covered	Global
No. of Companies Mentioned	6

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5083EUR$5,500USD£4,241GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6100EUR$6,600USD£5,089GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7320EUR$7,920USD£6,107GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8784EUR$9,504USD£7,328GBP

Report Scope

The report includes:

Table of Contents

Samples

Companies Mentioned

Table Information

Related Topics

Related Reports

Antibody-Drug Conjugates (ADC): Market Overview

Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028

Antibody Drug Conjugate - Competitive landscape, 2023

Antibody Drug Conjugates Global Market Report 2024

Global Antibody Drug Conjugates Market 2024-2028